Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas

Description

This research study is designed to find out if radiation therapy treatment prior to surgery is safe and effective to treat soft tissue sarcomas. 30 participants with soft tissue sarcoma will be enrolled and can expect to be on study for up to 5 years.

Conditions

Soft Tissue Sarcoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This research study is designed to find out if radiation therapy treatment prior to surgery is safe and effective to treat soft tissue sarcomas. 30 participants with soft tissue sarcoma will be enrolled and can expect to be on study for up to 5 years.

Phase II Trial of Neoadjuvant Hypofractionated Radiotherapy Versus Conventionally Fractionated Radiotherapy for Soft Tissue Sarcomas

Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas

Condition
Soft Tissue Sarcoma
Intervention / Treatment

-

Contacts and Locations

Madison

University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States, 53705

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Biopsy proven soft tissue sarcoma of the extremity, trunk, or head and neck
  • * No prior sarcoma-directed chemotherapy or radiotherapy
  • * Age ≥ 18 years
  • * Karnofsky performance status ≥ 60
  • * Able to understand and sign an informed consent
  • * Life expectancy of greater than 12 weeks
  • * Hypofractionated or conventionally fractionated radiotherapy using Intensity Modulated Radiation Therapy (IMRT) are both deemed feasible and safe neoadjuvant treatments, at the treating physician's discretion
  • * Operable disease and medically fit for surgery, based on the opinion of the consulting surgeon; surgery within 5-14 days of completion of radiation therapy (RT)
  • * Adequate bone marrow function as defined by absolute neutrophil count \> 500/mcL, hemoglobin \> 8 g/dL, platelets \> 50,000/mcL; adequate renal function as defined by creatinine clearance \> 30 mL/min
  • * Pregnant
  • * Unable to undergo imaging or positioning necessary for radiotherapy planning

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Wisconsin, Madison,

Zachary Morris, MD, PhD, PRINCIPAL_INVESTIGATOR, UW School of Medicine and Public Health

Study Record Dates

2026-11